VALNEVA SE EO -_15
Commented by Carsten Mainitz on April 21st, 2022 | 12:57 CEST
Valneva, Power Nickel, K+S: The perfect mix for traders and long-term investors!
As is well known, the profit lies in the purchase. On the question of how quickly and in what amount this should be realized, traders and long-term investors certainly have quite different answers. The current market phase is interesting for both types of investors. For many sectors, such as commodities or life science, the general conditions are good, so the wave of success can be ridden further. Increased fluctuations also offer short-term opportunities.
Read
Commented by Nico Popp on April 20th, 2022 | 10:29 CEST
The million-dollar opportunity: Valneva, Edgemont Gold, BASF
No one can see into the future. But investors can estimate which topics will move share prices in the near future. There is not always a connection between what is important and what is played out in the media. Issues such as climate change are timeless but disappear from the front pages from time to time. It is currently a similar situation with the pandemic. We dare to take a look into the future and ask what could move prices this summer.
Read
Commented by André Will-Laudien on April 19th, 2022 | 10:49 CEST
Watch out: BioNTech, NervGen, Valneva, CureVac: The next waves of biotech stocks are rolling!
The start of spring - and where to now? The mild flu outbreaks due to the Omicron variant and associated massive relaxations of Corona measures in many countries are weighing on the prospects of vaccine manufacturers in the short term. After all, there are no clinical bottlenecks, and the vaccination rate does not want to increase despite massive public campaigns. Mandatory vaccination is also off the table, and for the biotech industry and vaccine producers, this results in a need to keep researching other topics! Many diseases are more dangerous for us humans than Corona. We look at important protagonists.
Read
Commented by André Will-Laudien on April 1st, 2022 | 12:43 CEST
BioNTech, Defence Therapeutics, Valneva, CureVac - Stocks with blockbuster potential!
With the Ukraine crisis, international vaccination activity has taken a back seat. The world's northern hemisphere is gearing up for next summer, so flu diseases are also slowly taking a back seat. However, the COVID virus will likely continue to mutate over the summer and will reappear in a new guise in the fall. Germany's maximum vaccination rate of 76% has been reached, with just under a quarter of the population ultimately foregoing vaccination after lengthy public measures. For the major biotech companies, it is now a case of - The country needs new products! There are still many areas of application in the field of mRNA. Which stocks stand out with their pipeline?
Read
Commented by Juliane Zielonka on March 29th, 2022 | 13:34 CEST
Valneva, Triumph Gold, BioNTech - Gold rush mood in the pipeline
While the Corona measures are eased in Spain, and the government lets symptom-free positive tested persons out of quarantine, Germany tightens again and extends the measures. This could create a gold-rush mood among BioNTech investors, as figures from the Mainz-based biotech Company will be announced on Wednesday. Valneva is also looking ahead with confidence to the first shipment of its liquid gold in the form of the COVID-19 inactivated vaccine. For investors with a more earthy disposition, it is a good idea to look at the real precious metals and gold deposits these days. For example, an investment in Canada's Triumph Gold Corporation offers copper and diamond deposits in addition to gold. The Company specializes in the discovery and development of gold and other valuable commodity deposits.
Read
Commented by André Will-Laudien on March 21st, 2022 | 13:10 CET
Attention - MorphoSys, Valneva, CureVac, MAS Gold: These shares smell of a turnaround!
The biotech sector, especially around vaccine manufacturers, has recently fallen somewhat out of fashion - Germany's most extensive Corona measures have likely already taken place. The general willingness to vaccinate can hardly be increased, and the vaccination obligation was dropped without a trace after lawyers formed a massive wave of lawsuits. But now that the Omicron infection figures are exploding to unimagined heights, we can expect a hot autumn again after a summer with a breather. "Corona has come to stay!" said Karl Lauterbach when he was not yet health minister. We take a look at some shares that have recently rebounded strongly.
Read
Commented by Carsten Mainitz on March 16th, 2022 | 11:18 CET
Valneva, Perimeter Medical Imaging AI, Bayer - Immune to the crisis?
No sooner did the Corona pandemic seem to be under control than the world was shocked by the invasion of Russian troops in Ukraine. So far, the stock markets have digested the whole situation well. But even without further escalation, the supply situation for raw materials, among other things, will become more complex. The first signs are already awaiting us at the gas pumps. The rise in inflation will continue. Where should one invest given this mixed situation? Regardless of the economic and security situation, stocks from the healthcare sector are a good choice. Beyond fighting viruses or infectious diseases, there are great growth areas. Cancer is one such area. In addition, medical technology is increasingly bringing innovative technologies to the market, in some cases in conjunction with artificial intelligence, with disruption potential.
Read
Commented by Armin Schulz on March 7th, 2022 | 13:05 CET
Valneva, Defence Therapeutics, MorphoSys - Blockbuster potential
Every pharmaceutical or biotech company wants a blockbuster. This term refers to a drug that generates annual sales of at least USD 1 billion. The best-known blockbuster drug currently is the Corona vaccine from BioNTech. In 2020, the rheumatism drug Humira was in the top spot with sales of over USD 20 billion. The Mainz-based vaccine manufacturer is likely to have significantly surpassed this mark in 2021. If a company hits the big time, it can reap the rewards for 20 years before the patent expires. Today, we take a look at three companies that have potential blockbusters.
Read
Commented by Armin Schulz on March 2nd, 2022 | 11:24 CET
BioNTech, XPhyto Therapeutics, Valneva - Where are the Corona winners?
Even if the Corona coverage, which has prevailed for 2 years, has recently been replaced by the Ukraine conflict, the pandemic is not yet over. RKI chief Wieler recently reported increased outbreaks in nursing homes and rising incidences among the elderly. Health Minister Lauterbach also sees the wave not yet broken and reports the highest death rates in months. Since the legal basis for the Corona measures expires on March 19, a new law has been introduced to allow measures to be enacted beyond that date. Which companies could benefit?
Read
Commented by André Will-Laudien on February 22nd, 2022 | 13:05 CET
BioNTech, Moderna, Valneva, Cardiol Therapeutics: The gold rush is over!
The mild progression of the Omicron variant and the associated massive relaxations of the Corona measures in many countries weighs heavily on the prospects of the vaccine manufacturers. That is because the winter is drawing to a close, clinical shortages are not occurring, and vaccination rates do not want to increase despite massive public campaigns. Meanwhile, even those in power realize that enforcing a general vaccination requirement could become a hot legal ride under the current circumstances. For the biotech sector and vaccine producers, in particular, this is a reason for profit-taking for the time being. Here are a few further ideas.
Read